Next-generation sequencing facilitates genetic diagnosis and improves the management of patients with hearing loss in clinical practice

• Published in: International journal of pediatric otorhinolaryngology 2022-10, Vol.161, p.111258-111258, Article 111258
• Main Authors: Liu, Chang, Huang, Yanlin, Zhang, Yan, Ding, Hongke, Yu, Lihua, Wang, Anshi, Wang, Yunan, Zeng, Yukun, Liu, Ling, Liu, Yuan, Qi, Yiming, Li, Fake, Wu, Jing, Du, Li, Mai, Fei, Zhang, Qi, Wang, Xingwang, Yin, Aihua
• Format: Article
• Language: English
• Subjects: Clinical evaluation; Hearing loss; Molecular analysis; Next-generation sequencing
• ISSN: 0165-5876; 1872-8464
• DOI: 10.1016/j.ijporl.2022.111258

Hearing loss (HL) is a prevalent sensorineural disorder, and is among the most etiologically heterogeneous disorders. With the advent of next-generation sequencing (NGS) technologies, hundreds of candidate genes can be analyzed simultaneously in a cost-effective manner. Ninety-four patients from 87 families diagnosed with non-syndromic or syndromic HL were enrolled. A custom-designed HL panel and clinical exome sequencing (CES) were applied to explore molecular etiology in the cohort, and the efficacy of the two panels was examined. The etiologic diagnosis for HL has been identified for 36 out of 87 probands (41.4%), 28 with an autosomal recessive (AR) inheritance pattern and 8 with an autosomal dominant (AD) pattern. Candidate variants in 18 different genes were identified in the study cohort, 10 with AR inheritance pattern and 8 with AD pattern. Fourteen of the variants identified in the study were novel. The custom-designed HL panel covers almost all known HL-associated genes, and can be used as an effective clinical diagnostic platform; CES evaluates all exons related to clinical symptoms, and is also suitable for clinical diagnosis of HL. Next-generation sequencing facilitates genetic diagnosis and improves the management of patients with HL in the clinical practice.